OakChart

Black Diamond Therapeutics Inc

BDTXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 10:11 AM ET

1.600.00 (0.00%)
2026-11-11 16:12 CET
Market cap
91.64 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-44.07 USD m
Free cash flow, TTM
-33.33 USD m
EPS diluted, TTM
-0.77
P/E
-
Compare

Price

BDTX against its 20, 50 and 200-day averages
2050200beatmiss
2.003.004.004.3M8.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BDTXclose 1.6020-day 1.8150-day 1.88200-day 2.161.60

67.7% under 4.94 on 12 Nov 2025. Last 15 sessions, 33.2% high to low

Profile

BDTX
52-week range, 1% of the way up
1.584.94

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

IndexRUT
Employees21
IPOJan 30, 2020
Beta3.47
ATR, 14d0.15
Rel volume1.92
Short float11.06%
Insider own19.67%
Inst own53.87%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap91.64M
Enterprise Value5.65M
Income-44.07M
Sales0.00M
Book/sh1.53
Cash/sh1.78
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees21
IPOJan 30, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.04
P/C0.90
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.92
Current Ratio6.92
Debt/Eq0.18
LT Debt/Eq0.14
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.77
EPS next Y-0.94
EPS next Q-0.19
EPS this Y-280.13%
EPS next Y-33.45%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-302.37%
Sales Y/Y TTM-100.00%
EPS Q/Q-16.74%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.-81.24% -100.00%

Ownership

Insider Own19.67%
Insider Trans0.00%
Inst Own53.87%
Inst Trans-5.56%
ROA-32.25%
ROE-41.14%
ROIC-44.00%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-11.87%
SMA50-15.01%
SMA200-26.09%
Trades-

Technical

Shs Outstand57.47M
Shs Float46.15M
Short Float11.06%
Short Ratio7.44
Short Interest5.11M
52W High4.94 -67.71%
52W Low1.58 0.95%
Volatility12.30% 9.13%
ATR (14)0.15
RSI (14)41.05
Beta3.47
Rel Volume1.92
Avg Volume686.66K
Volume197,661

Performance

Perf Week-16.05%
Perf Month-5.06%
Perf Quarter-21.04%
Perf Half Y-44.23%
Perf YTD-34.36%
Perf Year-65.48%
Perf 3Y-10.39%
Perf 5Y-79.89%
Perf 10Y-
Recom1.38
Target Price10.86
Prev Close1.60
Price1.60
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Dec 03, 2025DowngradeGGuggenheimBuy → Neutral
Nov 18, 2025ResumedPPiper SandlerOverweight$9+464.3%
Oct 16, 2025ResumedSStifelBuy$8+401.6%
Sep 04, 2025InitiatedGGuggenheimBuy$8+401.6%
Jul 01, 2025ResumedRRaymond JamesOutperform$11+589.7%
Jul 31, 2024InitiatedRRaymond JamesOutperform$20+1,153.9%
Jul 14, 2023InitiatedPPiper SandlerOverweight
Jun 30, 2023UpgradeSStifelHold → Buy$2 → $10+527.0%
Jun 28, 2023UpgradeHH.C. WainwrightNeutral → Buy$11+589.7%
Jun 27, 2023UpgradeWWedbushNeutral → Outperform$10+527.0%

Peers

Mkt cap
TickerCompanyMkt cap
BLSMBlossomHill Therapeutics Inc486.31M
AVBPArriVent BioPharma Inc710.15M
TYRATyra Biosciences Inc1.43B
ELVNEnliven Therapeutics Inc3.76B
ERASErasca Inc5.67B
BBOTBridgeBio Oncology Therapeutics Inc204.44M
ORICORIC Pharmaceuticals Inc922.43M
KZIAKazia Therapeutics Limited ADR87.55M
NVCTNuvectis Pharma Inc718.08M
RLAYRelay Therapeutics Inc4.37B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SMLFiShares U.S. Small-Cap Equity Factor ETFAUM: 4.26B
DFSVUS Small Cap Value Portfolio ETF Class Shares-
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
BSVOEA Bridgeway Omni Small-Cap Value ETFAUM: 2.44B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 206
  • Black Diamond: Q3 Earnings Snapshot (Associated Press) -14.25%
  • Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update (GlobeNewswire)
  • Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC (GlobeNewswire) +7.20%
  • Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Black Diamond: Q2 Earnings Snapshot (Associated Press) +7.26%
  • Loading…
  • Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -35.77%
  • Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations (GlobeNewswire)
  • Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC (GlobeNewswire) +16.28%
  • Black Diamond: Q1 Earnings Snapshot (Associated Press)
  • Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting (GlobeNewswire)
  • Black Diamond: Q4 Earnings Snapshot (Associated Press Finance)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.170-0.094-0.1700.008.338
2026Q22026-08-05-0.170-0.195-0.1730.000.009
2026Q12026-05-07-0.160-0.184-0.1580.000.009
2025Q42026-03-16-0.270-0.179-0.2650.000.009
2025Q32025-11-06-0.150-0.234-0.1490.000.007
2025Q22025-08-07-0.190-0.248-0.1860.000.004
2025Q12025-05-120.9800.0210.98070.0035.004
2024Q42025-03-06-0.280-0.315-0.2820.000.007
2024Q32024-11-05-0.280-0.373-0.2750.000.007
2024Q22024-08-06-0.360-0.387-0.3610.000.007
2024Q12024-05-09-0.350-0.434-0.3520.000.006
2023Q42024-03-12-0.340-0.466-0.3760.000.005
2023Q32023-11-06-0.450-0.487-0.4520.000.006
2023Q22023-08-11-0.520-0.535-0.5250.000.006
2023Q12023-05-09-0.570-0.608-0.5720.000.004
2022Q42023-03-09-0.590-0.627-0.5790.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-16.990-6.617-0.9820.000.00
2020FY-2.050-2.011-2.0440.000.00
2021FY-3.470-3.707-3.4710.000.00
2022FY-2.520-2.555-2.5100.000.00
2023FY-1.880-1.984-1.8760.000.00
2024FY-1.270-1.299-1.2660.000.00
2025FY0.3900.4470.39070.0070.00
2026FY--0.703--0.00
2027FY--0.938--0.00
2028FY--0.929--0.00
2029FY--0.964--11.55
2030FY--0.392--86.70

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-106000.000.000.00
2026Q4S2026-08-206000.000.000.00
2026Q4S2026-08-067000.000.000.00
2026Q4S2026-05-077000.000.000.00
2026Q4S2026-03-197000.000.000.00
2026Q4S2026-03-176000.000.000.00
2026Q4S2025-11-146000.000.000.00
2026Q4S2025-11-115000.000.000.00
2026Q4S2025-11-105000.000.000.00
2026Q4R2026-11-10831-0.19-0.25-0.13
2026Q4R2026-10-20800-0.20-0.30-0.13
2026Q4R2026-08-20824-0.20-0.30-0.13
2026Q4R2026-08-06925-0.20-0.30-0.13
2026Q4R2026-08-04900-0.20-0.32-0.12

Estimate history

EPS, annual-0.128-0.249-0.982-2.044-3.471-2.51-1.876-1.2660.389-0.7696
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.275-0.2820.98-0.186-0.149-0.265-0.158-0.173-0.174
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000700
Period201720182019202020212022202320242025TTM
Sales, quarterly0070000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual35.91135.91135.91136.07836.23536.43451.64656.64557.13857.468
Period201720182019202020212022202320242025MRQ
Shares, quarterly56.52256.64556.67756.88756.94357.13857.30257.44657.468
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.0070.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.150.330.340.443.242.220.600.050.04
Gross Profit-0.1569.67-0.34-0.44-3.24-2.22-0.60-0.05-0.04
Selling, General and Administrative Excl. Other45.5549.8075.4986.0289.59124.6668.9729.298.86
Research and Development27.5233.2350.9758.9161.2094.6147.6121.716.95
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-45.7019.87-75.84-86.46-92.83-126.87-69.57-29.33-8.90
Interest Expense0.000.000.000.000.000.000.00--
Unusual Expense7.357.352.940.000.000.000.006.390.01
Net Income Before Taxes-44.0722.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-44.0722.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93
Net Income From Continuing Operations-44.0722.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93
Net Income-44.0722.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93
EPS (Recurring)-0.680.48-1.23-1.88-2.51-3.47-2.04-0.86-0.25
EPS (Basic, Before Extraordinaries)-0.770.39-1.27-1.88-2.51-3.47-2.04-0.98-0.25
EPS (Diluted)-0.770.39-1.27-1.88-2.51-3.47-2.04-0.98-0.25
EBITDA-45.5520.20-75.49-86.02-89.59-124.66-68.97-29.29-8.86
Non-Operating Income (Expense)8.989.859.114.021.661.282.320.47-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.606.6310.639.6012.2014.047.763.640.06
Price To Sales Ratio-2.00-------
Gross Margin-99.54-------
Operating Margin-28.39-------
Net Margin-31.95-------
Shares Outstanding57.4757.1456.6451.6536.4336.2336.0835.9135.91
Market Capitalization91.6491.64121.09145.0965.46193.101,153.661,166.62-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.0070.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.070.090.090.090.09
Gross Profit-0.03-0.03-0.03-0.07-0.09-0.0969.91-0.09
Selling, General and Administrative Excl. Other12.0912.0311.2310.2010.8913.3315.3818.19
Research and Development6.957.376.986.237.359.2310.4212.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.12-12.06-11.26-10.26-10.98-13.4254.53-18.27
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.007.350.000.000.000.00
Net Income Before Taxes-10.01-9.90-9.04-15.12-8.50-10.5656.54-15.98
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-10.01-9.90-9.04-15.12-8.50-10.5656.54-15.98
Net Income From Continuing Operations-10.01-9.90-9.04-15.12-8.50-10.5656.54-15.98
Net Income-10.01-9.90-9.04-15.12-8.50-10.5656.54-15.98
EPS (Recurring)-0.17-0.17-0.16-0.17-0.15-0.190.98-0.28
EPS (Basic, Before Extraordinaries)-0.17-0.17-0.16-0.26-0.15-0.191.00-0.28
EPS (Diluted)-0.17-0.17-0.16-0.26-0.15-0.190.98-0.28
EBITDA-12.09-12.03-11.23-10.20-10.89-13.3354.62-18.19
Non-Operating Income (Expense)2.112.152.222.492.482.862.012.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.231.511.451.411.741.781.701.64
Price To Earnings Ratio--5.606.7016.0140.19--
Price To Sales Ratio---1.983.082.011.28-
Gross Margin------99.88-
Operating Margin------77.90-
Net Margin------80.77-
Shares Outstanding57.4757.4557.3057.1456.9456.8956.6856.64
Market Capitalization91.64106.01122.02138.45215.78141.0287.83121.09

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments128.6598.58131.40122.81209.79315.07154.6751.667.88
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.792.602.634.905.924.491.050.020.04
Total Current Assets132.44101.18134.03127.71215.70319.55155.7151.687.91
Net Property, Plant & Equipment9.6720.4023.7127.3830.748.790.160.130.10
Total Investments and Advances0.830.820.821.171.221.220.060.000.00
Intangible Assets--0.000.00-----
Other Assets0.070.250.000.000.020.112.360.010.01
Total Assets143.01122.64158.57156.25247.68329.67158.2951.838.02
Short Term Debt Incl. Current Port. of LT Debt3.713.403.112.840.321.050.000.000.00
Accounts Payable0.584.012.321.884.112.541.960.420.15
Other Current Liabilities11.4413.1614.2110.5419.2110.632.902.162.08
Total Current Liabilities15.7320.5719.6515.2623.6414.224.862.582.23
Long Term Debt15.0718.7822.1825.3028.147.69200.5760.7712.46
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.024.020.01
Total Liabilities30.8039.3541.8340.5651.7821.91205.4567.3714.70
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity112.2183.28116.74115.69195.90307.76-47.16-15.54-6.67
Total Shareholders Equity112.2183.28116.74115.69195.90307.76-47.16-15.54-6.67
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity112.2183.28116.74115.69195.90307.76-47.16-15.54-6.67
Total Liabilities & Stockholders Equity143.01122.64158.57156.25247.68329.67158.2951.838.02
Book Value Per Share1.961.472.263.185.418.53-1.31-0.43-0.19
Tangible Book Value Per Share1.961.472.263.185.418.53-1.31-0.43-0.19
Full-Time Employees21245465887332--
Price to Book Ratio1.041.241.080.490.993.763.56--
Return on Assets16.84-49.55-52.37-45.14-43.51-27.57-33.56-29.85-
Return on Equity22.88-69.67-70.94-58.52-49.87-51.61---
Return on Invested Capital17.57-68.26-59.34-64.66-56.06-21.32-22.98-19.75-79.58
Quick Ratio8.424.926.828.379.1222.4832.0220.073.55
Current Ratio8.424.926.828.379.1222.4832.0220.073.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-44.0722.37-69.68-82.44-91.17-125.60-67.25-35.26-8.93
Depreciation0.150.330.340.443.242.220.600.050.04
Other Funds (Non Cash)15.5015.659.7211.6012.7516.219.4710.070.08
Funds from Operations-28.4238.34-59.61-70.40-75.18-107.17-57.19-25.14-8.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4.90-8.73-2.693.69-9.907.025.040.460.35
Cash from Operating Activities-33.3329.61-62.30-66.72-85.08-100.15-52.15-24.67-8.45
Capital Expenditures0.000.000.00-0.03-0.19-2.71-0.14-0.02-0.08
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.030.090.100.010.000.000.000.00
Purchase or Sale of Investments17.70-44.9316.8716.2853.55133.32-281.550.000.00
Purchase of Investments-76.31-164.03-122.88-61.89-60.14-49.51-372.480.000.00
Sale Or Maturity of Investments94.01119.09139.7578.17113.69182.8390.930.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities17.70-44.9116.9716.3553.37130.61-281.69-0.02-0.08
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-0.20-0.1525.5571.930.180.73214.94127.7652.31
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-0.20-0.1525.5571.930.180.73214.94127.7652.31
Proceedsfrom Stock Options0.000.0024.4971.850.000.00213.84127.7652.31
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.040.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-0.15-0.1525.5571.930.180.73214.94127.7652.31
Net Change in Cash-15.77-15.44-19.7921.56-31.5431.19-118.89103.0643.78
Free Cash Flow-33.3329.61-62.30-66.75-85.27-102.86-52.29-24.70-8.53
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-4.72-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments102.03110.51118.26128.65135.50142.83
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.514.894.713.793.493.90
Total Current Assets106.54115.39122.97132.44138.99146.73
Net Property, Plant & Equipment7.938.529.109.6717.8018.67
Total Investments and Advances0.830.830.830.830.830.82
Other Assets0.250.280.030.070.120.16
Total Assets115.56125.03132.92143.01157.73166.38
Short Term Debt Incl. Current Port. of LT Debt3.963.883.793.713.633.78
Accounts Payable1.041.402.970.580.970.77
Other Current Liabilities10.4110.567.7711.4410.9412.25
Total Current Liabilities15.4015.8414.5315.7315.5416.80
Long Term Debt12.0813.1014.0915.0716.0416.97
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities27.4828.9428.6230.8031.5833.77
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity88.0896.09104.30112.21126.15132.61
Total Shareholders Equity88.0896.09104.30112.21126.15132.61
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity88.0896.09104.30112.21126.15132.61
Total Liabilities & Stockholders Equity115.56125.03132.92143.01157.73166.38
Book Value Per Share1.531.671.821.962.222.33
Tangible Book Value Per Share1.531.671.821.962.222.33
Full-Time Employees---21--
Price to Book Ratio1.041.021.081.101.630.99
Return on Assets-32.25-29.21-27.9516.8414.549.13
Return on Equity-41.14-37.21-35.1622.8819.2311.85
Return on Invested Capital-10.00-9.07-7.63-11.88-5.98-7.06
Quick Ratio6.927.288.468.428.948.73
Current Ratio6.927.288.468.428.948.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-10.01-9.90-9.04-15.12-8.50-10.56
Depreciation0.030.030.030.070.090.09
Other Funds (Non Cash)2.521.891.839.252.242.12
Funds from Operations-7.46-7.99-7.18-5.80-6.17-8.35
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.880.02-3.05-0.99-1.68-0.81
Cash from Operating Activities-8.34-7.97-10.23-6.79-7.85-9.16
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.01
Purchase or Sale of Investments4.22-3.1219.50-2.898.59-59.16
Purchase of Investments-22.28-18.120.00-35.90-14.91-89.75
Sale Or Maturity of Investments26.5015.0019.5033.0123.5030.58
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities4.22-3.1219.50-2.898.59-59.15
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.00-0.200.13-0.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.00-0.200.13-0.12
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.010.22-0.180.000.000.00
Other Financing Activities Uses0.000.18-0.180.000.000.00
Cash from Financing Activities0.010.22-0.18-0.200.13-0.12
Net Change in Cash-4.11-10.889.08-9.870.87-68.43
Free Cash Flow-8.34-7.97-10.23-6.79-7.85-9.16
Price to Free Cash Flow---4.6810.11-

Revenue breakdown

Biological Products, (No Diagnostic Substances)2025: 70.00M
United States2025: 70.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.06%5.1M46.2M683.21K
2026-10-1510.84%5.0M46.2M619.81K
2026-09-3010.35%4.8M46.2M758.25K
2026-09-1511.15%5.1M46.2M1.06M
2026-08-3113.26%6.1M46.1M1.20M
2026-08-1413.41%6.2M46.1M1.64M
2026-07-3112.71%5.9M46.1M1.71M
2026-07-1512.72%5.9M46.0M1.76M
2026-06-309.78%4.5M46.0M1.62M
2026-06-1510.83%5.0M46.0M1.27M
2026-05-2913.11%6.0M46.0M1.18M
2026-05-1511.44%5.3M46.0M742.35K
2026-04-309.96%4.5M45.0M706.17K
2026-04-1512.16%5.5M45.0M707.24K
2026-03-3111.26%5.1M45.0M725.70K
2026-03-1311.24%5.1M45.0M809.32K
2026-02-2710.34%4.6M44.8M1.06M
2026-02-139.22%4.1M44.8M1.15M
2026-01-309.24%4.1M44.8M1.22M
2026-01-158.39%3.8M44.8M1.19M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.651.650.0032.8180.000.000.952-0.0090.000
call1.000.151.150.0011.7300.000.000.880-0.0320.001
call1.500.000.950.6910.10361.000.000.841-0.0410.001
call2.000.000.200.103.67738.000.000.472-0.0210.001
call2.500.000.200.052.4001230.000.175-0.0080.001
call5.000.000.150.004.4500.000.000.116-0.0120.001
call7.500.002.600.007.2560.000.000.223-0.0300.001
put0.500.000.050.046.1161.000.00-0.048-0.0080.000
put1.000.001.000.007.7190.000.00-0.157-0.0250.001
put1.500.001.000.1012.5501600.00-0.161-0.0410.001
put2.000.001.000.357.35114.000.00-0.568-0.0180.001
put2.500.401.400.007.3150.000.00-0.626-0.0220.001
put5.001.605.100.000.0000.000.00-0.755-0.0260.001
put7.504.107.600.000.0000.000.00-0.776-0.0300.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-27SCHEDULE 13GSEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-298-KCurrent report2026-06-26SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-19SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-19SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-26SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-20SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-20SEC
2026-03-1610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-168-KCurrent report2026-03-16SEC
2026-03-16S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-02-17SCHEDULE 13G/ASEC
2026-01-234Statement of changes in beneficial ownership of securities2026-01-21SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
NEA Management Company, LLC7.76%
T. Rowe Price Investment Management, Inc.7.03%
BlackRock, Inc.6.84%
ACADIAN ASSET MANAGEMENT LLC4.09%
VANGUARD CAPITAL MANAGEMENT LLC3.71%
RENAISSANCE TECHNOLOGIES LLC3.42%
Defilade Capital Management, L.P.2.92%
GEODE CAPITAL MANAGEMENT, LLC2.17%
Connor, Clark & Lunn Investment Management Ltd.1.95%
AWM Investment Company, Inc.1.75%

Funds

Fund% owned
T. Rowe Price Small-Cap Value Fund, Inc.3.70%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.72%
iShares Russell 2000 ETF2.11%
Fidelity Enhanced Small Cap Core ETF0.91%
Fidelity Small Cap Index Fund0.90%
VANGUARD EXTENDED MARKET INDEX FUND0.89%
iShares U.S. Small-Cap Equity Factor ETF0.82%
iShares Russell 2000 Value ETF0.81%
Ultra-Small Company Fund0.65%
iShares Biotechnology ETF0.61%

OakChart. BDTX. Cached 15 minutes.

Some panels did not load: insider.